Medvi Tirzepatide Review Pricing Explained: Medication, Membership, Labs, and Shipping

Compounded plans are sold as a single monthly subscription with shipping included and no separate membership line. The company’s own January 2026 announcement listed compounded injections at $179 for the first month and $299 for refills, with compounded tablets from $249. Brand-name options use a different model: a $99 membership plus the cost of the medication.

Two pricing models under one roof

This is the detail that trips up side-by-side tables. The compounded tiers are bundled, and the marketing copy states there is no membership or hidden fee. The brand tiers are not bundled: Wegovy in pill and injection form, and Zepbound injection, are each presented as a $99 membership plus medication cost, with availability described as subject to change. Comparing a bundled compounded figure against a rival’s unbundled brand figure produces nonsense, and comparing the two models inside this one program produces the same nonsense.

The bundled subscription is described as covering clinician review and consultations, the medication, portal access, patient support, and delivery. Free expedited delivery appears as a stated guarantee alongside doctor-led plans and no hidden fees. Nothing in that list is exotic for the category; the point of examining it is to find the lines that sit outside it.

Why the exact figure is not a fixed number

Two things make the advertised rate a starting point rather than a contract. First, the price on the main GLP-1 landing page is delivered as a dynamic offer variable rather than a printed figure, so what a given visitor sees depends on the promotion attached to their session. Second, and more consequential, the user agreement states that the final charge to a card may vary depending on the medication prescribed and the pharmacy chosen to fulfill the order, with support communicating any difference.

That clause is honest and it is also the single most important sentence in the pricing discussion. A subscription whose amount can move with the dispensing pharmacy is not a flat rate in the way a shopper reading a landing page would assume. Anyone budgeting should record the figure shown at checkout and compare it against the first two statements rather than against the advertisement.

Because that variance is baked in, checking published rates from more than one provider is the only way to know what normal looks like. Hims and Hers, Henry Meds, and Ro each post compounded GLP-1 pricing, HealthRX shows its tirzepatide membership and refill figures, and manufacturer self-pay routes like LillyDirect price approved product on their own pages. A single advertised number means little until it sits next to three or four of those.

The dietitian asterisk and the labs question

Free dietitian visits and care coaching are promoted as included, with an asterisk. The asterisk says those are free to end users subject to insurance and copay eligibility, determined at the time of the visit. In other words, the nutrition benefit is billed through a health plan, and a cash-pay patient without applicable coverage may find it is not free at all. That is disclosed rather than hidden, and it is easy to miss.

Laboratory work sits in a similar gray zone. The refund policy describes the subscription price as potentially including lab services among other items, while the user agreement states the affiliated medical entities are out of network with all health plans and that medication or laboratory services ordered by a provider may not be covered. Both statements can be true depending on how a lab is ordered, which means labs are a question to settle with support in writing before enrollment rather than a line to assume.

Cost line	How the compounded plan handles it	How the brand tier handles it	What to confirm at checkout
Medication	Inside the monthly subscription	Billed separately from the membership	The refill figure, not the first-month figure
Membership	None charged separately	$99 per month	Whether it continues during a pause
Consultation	Included in the subscription	Included in the membership	That consult fees are non-refundable once used
Shipping	Included, promoted as expedited	Included	Reship terms after a delivery failure
Labs	May be included, may be billed	Same ambiguity	Who orders them and who is billed
Dietitian access	Free subject to insurance and copay eligibility	Same asterisk	Cost if no plan applies
Insurance	Not billed, providers out of network	Not billed	Whether a receipt supports an HSA claim

The tablets are priced higher and evidenced less

Compounded daily tablets start above the injections and refill above them too. The stated reason is compounding cost, which is plausible. The clinical reason to hesitate is separate: there is no FDA-approved sublingual semaglutide or tirzepatide. The approved oral semaglutide product is a swallowed tablet whose labeling carries specific administration requirements around timing, fasting, and water volume, precisely because oral absorption of this molecule is difficult. Marketing that describes a dissolving compounded tablet as delivering benefits similar to an injection is asserting something no published trial has tested.

Compounded medication of any format is not FDA approved, and the agency does not review it for safety, effectiveness, or quality before sale. It also lists, among its telehealth warning signs, companies that claim a compounded drug is the same as an approved drug. That guidance applies with more force to a dosage form that has no approved analogue at all.

Annualizing it

Twelve months on the compounded injection plan at the published refill rate, after a discounted first month, lands in the low thousands before anything else. Add a baseline metabolic and lipid panel with an A1c, which is a small copay through primary care and a modest cash cost through a direct lab. Add nothing for insurance, since Medicare drug coverage has excluded medication used solely for weight loss and these providers do not contract with plans in any event.

Then run the same twelve-month math on the alternatives, at maintenance strength rather than starting strength. A competing supervised tirzepatide provider publishes a side-by-side breakdown of these figures, which is a reasonable place to see the structure laid out so long as every number is re-checked at its source before it enters a budget. Manufacturer self-pay channels for Zepbound and Wegovy belong in that comparison too, since they dispense approved product with approved labeling.

Frequently asked questions

Is there a membership fee on the compounded plans?

Not on the compounded tiers, which are marketed as a single monthly price with no membership or hidden fee. The brand-name options are structured differently, at $99 per month plus the medication cost. Anyone comparing this program against another needs to know which of the two tiers they are quoting.

Can the monthly charge change without the plan changing?

Yes. The user agreement states the final charge may vary depending on the medication prescribed and the pharmacy that fulfills the order, with support notifying the customer of any difference. That makes the advertised figure an opening quote rather than a locked amount, which is worth confirming in writing at enrollment.

Are the dietitian visits genuinely free?

They are free to end users subject to insurance and copay eligibility determined at the visit, according to the asterisk attached to the claim. For a cash-pay patient with no applicable coverage, that qualifier is the whole answer, and the benefit should not be counted as included until support confirms it in a specific case.

Do HSA or FSA funds apply?

The marketing states these programs are HSA and FSA approved. In practice, eligibility for medical expenses depends on plan rules and substantiation, and a card can be declined at the point of sale even for a qualifying expense. Confirming with the plan administrator beforehand avoids an awkward failed transaction.

How does this compare with the approved products?

Compounded programs sit well below brand self-pay channels, and the gap reflects regulatory status rather than a discount on the same item. Approved tirzepatide and semaglutide products carry labeling reviewed for safety, effectiveness, and manufacturing quality, and manufacturer self-pay rates change periodically and should be checked directly.

Sources

• FDA, Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss
• FDA, Compounding and the FDA: Questions and Answers. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
• DailyMed, Zepbound (tirzepatide) prescribing information. https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=ZEPBOUND
• DailyMed, Wegovy (semaglutide) prescribing information. https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=WEGOVY
• DailyMed, Rybelsus (oral semaglutide) prescribing information. https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=RYBELSUS
• Tirzepatide Once Weekly for the Treatment of Obesity, SURMOUNT-1. https://pubmed.ncbi.nlm.nih.gov/35658024/
• Pharmacotherapy for obesity management in adults, 2025 clinical practice guideline update. https://pubmed.ncbi.nlm.nih.gov/40789597/
• CMS, Prescription Drug Coverage General Information. https://www.cms.gov/medicare/coverage/prescription-drug-coverage